Milestone Pharmaceuticals (MIST) Competitors $1.49 +0.01 (+0.68%) (As of 09:27 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends MIST vs. VERU, SBBP, SLGL, FATE, RZLT, STRO, DSGN, PRQR, ZURA, and ADCTShould you be buying Milestone Pharmaceuticals stock or one of its competitors? The main competitors of Milestone Pharmaceuticals include Veru (VERU), Strongbridge Biopharma (SBBP), Sol-Gel Technologies (SLGL), Fate Therapeutics (FATE), Rezolute (RZLT), Sutro Biopharma (STRO), Design Therapeutics (DSGN), ProQR Therapeutics (PRQR), Zura Bio (ZURA), and ADC Therapeutics (ADCT). These companies are all part of the "medical" sector. Milestone Pharmaceuticals vs. Veru Strongbridge Biopharma Sol-Gel Technologies Fate Therapeutics Rezolute Sutro Biopharma Design Therapeutics ProQR Therapeutics Zura Bio ADC Therapeutics Veru (NASDAQ:VERU) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, community ranking, media sentiment, earnings, dividends and profitability. Which has higher valuation and earnings, VERU or MIST? Milestone Pharmaceuticals has lower revenue, but higher earnings than Veru. Veru is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVeru$16.30M6.59-$93.15M-$0.48-1.53Milestone Pharmaceuticals$1M78.84-$59.69M-$1.02-1.45 Is VERU or MIST more profitable? Milestone Pharmaceuticals has a net margin of 0.00% compared to Veru's net margin of -376.38%. Veru's return on equity of -115.99% beat Milestone Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Veru-376.38% -115.99% -66.94% Milestone Pharmaceuticals N/A -165.26%-55.71% Which has more volatility & risk, VERU or MIST? Veru has a beta of -0.47, meaning that its stock price is 147% less volatile than the S&P 500. Comparatively, Milestone Pharmaceuticals has a beta of 1.72, meaning that its stock price is 72% more volatile than the S&P 500. Does the MarketBeat Community favor VERU or MIST? Veru received 189 more outperform votes than Milestone Pharmaceuticals when rated by MarketBeat users. Likewise, 69.59% of users gave Veru an outperform vote while only 69.23% of users gave Milestone Pharmaceuticals an outperform vote. CompanyUnderperformOutperformVeruOutperform Votes27069.59% Underperform Votes11830.41% Milestone PharmaceuticalsOutperform Votes8169.23% Underperform Votes3630.77% Do insiders and institutionals hold more shares of VERU or MIST? 47.2% of Veru shares are owned by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. 14.2% of Veru shares are owned by company insiders. Comparatively, 9.9% of Milestone Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts rate VERU or MIST? Veru presently has a consensus target price of $4.00, suggesting a potential upside of 445.18%. Milestone Pharmaceuticals has a consensus target price of $12.00, suggesting a potential upside of 710.81%. Given Milestone Pharmaceuticals' higher possible upside, analysts clearly believe Milestone Pharmaceuticals is more favorable than Veru.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Veru 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Milestone Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to VERU or MIST? In the previous week, Veru's average media sentiment score of 0.00 equaled Milestone Pharmaceuticals'average media sentiment score. Company Overall Sentiment Veru Neutral Milestone Pharmaceuticals Neutral SummaryMilestone Pharmaceuticals beats Veru on 8 of the 14 factors compared between the two stocks. Ad Porter & CompanyThe Final FrontierAnd a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt to discredit it, tar and feather it, and convince you not to watch it. That’s because it tells the shocking truth about the current AI mania… and why investors in big tech companies like Nvidia, Meta, Alphabet, and Microsoft could be in for a whole world of pain.Here’s the full story for you. Get Milestone Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIST and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MIST vs. The Competition Export to ExcelMetricMilestone PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$78.84M$6.79B$5.11B$8.43BDividend YieldN/A7.94%7.56%4.16%P/E Ratio-1.4512.50126.1616.71Price / Sales78.84270.991,651.6576.32Price / CashN/A46.0937.4133.56Price / Book2.965.274.614.98Net Income-$59.69M$152.08M$116.32M$224.69M7 Day Performance3.50%-2.23%-0.96%-0.51%1 Month Performance-1.33%14.00%5.36%3.32%1 Year Performance-47.33%36.66%33.86%25.51% Milestone Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MISTMilestone Pharmaceuticals1.8522 of 5 stars$1.49+0.7%$12.00+705.4%-47.3%$79.37M$1M-1.4630Upcoming EarningsVERUVeru1.6434 of 5 stars$0.73-3.9%$4.00+445.2%-26.6%$107.40M$16.30M-1.53189Gap UpSBBPStrongbridge BiopharmaN/A$2.00flatN/A+0.0%$135.66M$30.73M-2.6772Analyst ForecastGap DownSLGLSol-Gel Technologies2.4416 of 5 stars$0.56+9.9%$5.00+799.3%-60.0%$15.49M$1.55M-1.0350Gap UpFATEFate Therapeutics3.5932 of 5 stars$2.76+13.6%$6.90+150.0%+15.5%$314.31M$63.53M-1.61550Gap UpRZLTRezolute3.8881 of 5 stars$5.44-1.1%$11.57+112.7%+444.0%$304.26MN/A-4.0940Upcoming EarningsAnalyst ForecastNews CoverageSTROSutro Biopharma4.1541 of 5 stars$3.69+3.9%$12.13+228.6%+29.5%$302.43M$153.73M-2.02240Upcoming EarningsDSGNDesign Therapeutics1.3635 of 5 stars$5.32+2.3%$7.00+31.6%+142.9%$301.22MN/A-5.9140Upcoming EarningsPRQRProQR Therapeutics2.9966 of 5 stars$3.63-2.7%$5.88+61.8%+200.0%$296.50M$7.05M-12.52180ZURAZura Bio2.5962 of 5 stars$4.37-0.2%$16.75+283.3%-10.5%$293.71MN/A0.003Upcoming EarningsAnalyst ForecastNews CoverageGap UpADCTADC Therapeutics2.433 of 5 stars$3.02+2.4%$9.00+198.0%+277.5%$292.00M$69.56M-1.18310Upcoming Earnings Related Companies and Tools Related Companies VERU Alternatives SBBP Alternatives SLGL Alternatives FATE Alternatives RZLT Alternatives STRO Alternatives DSGN Alternatives PRQR Alternatives ZURA Alternatives ADCT Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MIST) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredMissed Out On Nvidia?Artificial Intelligence is a tool with the potential to create massive distributions of wealth… In fact, it...Unstoppable Prosperity | SponsoredThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally c...Porter & Company | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Milestone Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Milestone Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
